The collaboration is expected to enhance the drug development projects and the ongoing Harvard research projects by creating a drug discovery bridge between academia and industry.
Under Harvard-UCB collaboration, the first research project funded for Gokhan Hotamisligil, Department of Genetics and Complex Diseases, chair, Harvard School of Public Health, for the creation of development of antibodies against a target with potential application in a range of diseases including diabetes and metabolic disorders.
UCB NewMedicines president Ismail Kola said the aim of our alliance with Harvard is to create a two-way exchange of knowledge and expertise that will facilitate the successful development of innovative new drugs.